Revenue growth has been uneven, with the latest quarter's 14.5% year-over-year increase following much slower prior growth, while gross margin improved to 56.8% but operating margin fell to 10.4% from 19.6% a year earlier, suggesting rising operating expenses are eroding gross profit gains.
Abbott Laboratories (ABT) annual income statement — 30-year revenue, gross profit & net income history
| Metric | TTM | Dec'25 | Dec'24 | Dec'23 | Dec'22 | Dec'21 | Dec'20 | Dec'19 | Dec'18 | Dec'17 | Dec'16 | Dec'15 | Dec'14 | Dec'13 | Dec'12 | Dec'11 | Dec'10 | Dec'09 | Dec'08 | Dec'07 | Dec'06 | Dec'05 | Dec'04 | Dec'03 | Dec'02 | Dec'01 | Dec'00 | Dec'99 | Dec'98 | Dec'97 | Dec'96 |
|---|
| Sales/Revenue | 48.23B | 44.33B | 41.95B | 40.11B | 43.65B | 43.08B | 34.61B | 31.9B | 30.58B | 27.39B | 20.85B | 20.41B | 20.25B | 21.85B | 39.87B | 38.85B | 35.17B | 30.77B | 29.53B | 25.91B | 22.48B | 22.34B | 19.68B | 19.68B | 17.68B | 16.29B | 13.75B | 13.18B | 12.48B | 11.88B | 11.01B |
| Revenue Growth % | 10% | 5.67% | 4.59% | -8.12% | 1.34% | 24.47% | 8.48% | 4.34% | 11.64% | 31.35% | 2.2% | 0.78% | -7.33% | -45.21% | 2.63% | 10.48% | 14.31% | 4.19% | 13.94% | 15.3% | 0.62% | 13.51% | -0% | 11.29% | 8.59% | 18.47% | 4.31% | 5.61% | 5% | 7.9% | 10% |
| Cost of Goods Sold | 20.72B | 19.72B | 20.63B | 20.07B | 21.33B | 19.86B | 17.23B | 15.21B | 14.76B | 14.32B | 9.61B | 9.45B | 9.76B | 9.8B | 10.64B | 15.41B | 14.57B | 13.15B | 12.48B | 11.33B | 9.63B | 10.47B | 8.88B | 9.47B | 8.51B | 7.75B | 6.24B | 5.98B | 5.39B | 5.05B | 4.73B |
| COGS % of Revenue | - | 44.49% | 49.17% | 50.04% | 48.86% | 46.11% | 49.79% | 47.68% | 48.25% | 52.3% | 46.08% | 46.29% | 48.19% | 44.86% | 26.68% | 39.67% | 41.44% | 42.73% | 42.28% | 43.71% | 42.86% | 46.86% | 45.14% | 48.14% | 48.1% | 47.58% | 45.39% | 45.36% | 43.23% | 42.46% | 42.97% |
| Gross Profit | 27.51B | 24.61B | 21.32B | 20.04B | 22.32B | 23.21B | 17.38B | 16.69B | 15.82B | 13.07B | 11.24B | 10.96B | 10.49B | 9.86B | 10.85B | 23.44B | 20.59B | 17.62B | 17.04B | 14.59B | 12.84B | 11.87B | 10.8B | 10.21B | 9.18B | 8.54B | 7.51B | 7.2B | 7.08B | 6.84B | 6.28B |
| Gross Margin % | 57.04% | 55.51% | 50.83% | 49.96% | 51.14% | 53.89% | 50.21% | 52.32% | 51.75% | 47.7% | 53.92% | 53.71% | 51.81% | 45.12% | 27.22% | 60.33% | 58.56% | 57.27% | 57.72% | 56.29% | 57.14% | 53.14% | 54.86% | 51.86% | 51.9% | 52.42% | 54.61% | 54.64% | 56.77% | 57.54% | 57.03% |
| Gross Profit Growth % | - | 15.39% | 6.43% | -10.24% | -3.84% | 33.59% | 4.1% | 5.5% | 21.1% | 16.2% | 2.59% | 4.48% | 6.42% | -9.19% | -53.7% | 13.83% | 16.88% | 3.37% | 16.85% | 13.58% | 8.18% | 9.96% | 5.77% | 11.21% | 7.51% | 13.71% | 4.26% | 1.65% | 3.59% | 8.86% | 10.46% |
| Operating Expenses | 20.28B | 16.59B | 14.47B | 13.6B | 13.96B | 14.01B | 12.09B | 12.1B | 11.98B | 11.09B | 8B | 8.01B | 7.57B | 7.71B | 8.85B | 16.6B | 13.54B | 11.05B | 10.96B | 9.64B | 8.51B | 7.22B | 6.62B | 6.78B | 5.54B | 6.64B | 4.25B | 4.05B | 3.97B | 3.99B | 3.66B |
| OpEx % of Revenue | - | 37.42% | 34.5% | 33.91% | 31.98% | 32.53% | 34.92% | 37.93% | 39.18% | 40.5% | 38.34% | 39.26% | 37.41% | 35.29% | 22.19% | 42.73% | 38.51% | 35.91% | 37.1% | 37.2% | 37.84% | 32.33% | 33.63% | 34.47% | 31.33% | 40.79% | 30.88% | 30.74% | 31.78% | 33.55% | 33.27% |
| Selling, General & Admin | 14.64B | 12.38B | 11.65B | 10.88B | 11.11B | 11.28B | 9.67B | 9.69B | 9.69B | 8.96B | 6.64B | 6.64B | 6.29B | 6.34B | 7.3B | 12.54B | 9.97B | 8.3B | 8.27B | 7.24B | 6.28B | 5.41B | 4.92B | 5.05B | 3.98B | 3.73B | 2.89B | 2.86B | 2.74B | 2.68B | 2.46B |
| SG&A % of Revenue | - | 27.92% | 27.77% | 27.13% | 25.45% | 26.18% | 27.94% | 30.38% | 31.69% | 32.73% | 31.83% | 32.55% | 31.06% | 29.02% | 18.32% | 32.27% | 28.35% | 26.99% | 28% | 27.93% | 27.94% | 24.22% | 25.01% | 25.66% | 22.5% | 22.93% | 21.05% | 21.68% | 21.99% | 22.59% | 22.33% |
| Research & Development | 3.29B | 2.96B | 2.82B | 2.72B | 2.85B | 2.74B | 2.42B | 2.41B | 2.29B | 2.13B | 1.36B | 1.37B | 1.29B | 1.37B | 1.54B | 4.06B | 3.57B | 2.74B | 2.69B | 2.4B | 2.23B | 1.81B | 1.7B | 1.73B | 1.56B | 1.58B | 1.35B | 1.19B | 1.22B | 1.3B | 1.2B |
| R&D % of Revenue | - | 6.67% | 6.73% | 6.78% | 6.53% | 6.36% | 6.99% | 7.55% | 7.48% | 7.78% | 6.51% | 6.71% | 6.35% | 6.28% | 3.87% | 10.45% | 10.16% | 8.92% | 9.11% | 9.27% | 9.9% | 8.11% | 8.62% | 8.81% | 8.83% | 9.69% | 9.83% | 9.06% | 9.79% | 10.96% | 10.94% |
| Other Operating Expenses | 4M | 1.25B | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating Income | 7.23B | 8.05B | 6.83B | 6.43B | 8.36B | 9.2B | 5.29B | 4.59B | 3.84B | 1.97B | 3.25B | 2.95B | 2.92B | 2.15B | 2.01B | 6.84B | 7.05B | 6.57B | 6.09B | 4.95B | 4.34B | 4.65B | 4.18B | 2.97B | 3.15B | 1.89B | 3.4B | 3.15B | 3.12B | 2.85B | 2.62B |
| Operating Margin % | 15% | 18.16% | 16.27% | 16.04% | 19.16% | 21.36% | 15.29% | 14.39% | 12.57% | 7.2% | 15.58% | 14.45% | 14.4% | 9.82% | 5.03% | 17.61% | 20.05% | 21.36% | 20.62% | 19.08% | 19.29% | 20.81% | 21.23% | 15.11% | 17.82% | 11.63% | 24.74% | 23.9% | 24.99% | 23.99% | 23.76% |
| Operating Income Growth % | - | 17.92% | 6.06% | -23.04% | -9.11% | 73.88% | 15.25% | 19.43% | 94.93% | -39.3% | 10.17% | 1.13% | 35.88% | 6.93% | -70.66% | -2.97% | 7.31% | 7.91% | 23.12% | 14.05% | -6.74% | 11.3% | 40.46% | -5.65% | 66.41% | -44.3% | 7.98% | 1.01% | 9.38% | 8.92% | 9.83% |
| EBITDA | 11.02B | 11.16B | 10.04B | 9.68B | 11.63B | 12.74B | 8.62B | 7.61B | 7.12B | 4.99B | 4.6B | 4.42B | 4.39B | 3.66B | 4.79B | 9.89B | 9.68B | 8.66B | 7.93B | 6.8B | 5.89B | 6.01B | 5.47B | 4.1B | 4.2B | 3.06B | 4.23B | 3.98B | 3.9B | 3.58B | 3.3B |
| EBITDA Margin % | 22.86% | 25.19% | 23.94% | 24.13% | 26.64% | 29.57% | 24.9% | 23.84% | 23.29% | 18.23% | 22.07% | 21.67% | 21.68% | 16.76% | 12.01% | 25.44% | 27.51% | 28.15% | 26.85% | 26.24% | 26.23% | 26.9% | 27.77% | 20.84% | 23.72% | 18.8% | 30.76% | 30.18% | 31.27% | 30.11% | 29.99% |
| EBITDA Growth % | 0.97% | 11.16% | 3.77% | -16.78% | -8.71% | 47.81% | 13.32% | 6.78% | 42.64% | 8.5% | 4.09% | 0.73% | 19.85% | -23.55% | -51.54% | 2.17% | 11.72% | 9.24% | 16.58% | 15.36% | -1.89% | 9.92% | 33.27% | -2.24% | 37.02% | -27.58% | 6.3% | 1.93% | 9.05% | 8.33% | 12% |
| D&A (Non-Cash Add-back) | 3.79B | 3.12B | 3.22B | 3.24B | 3.27B | 3.54B | 3.33B | 3.01B | 3.28B | 3.02B | 1.35B | 1.47B | 1.47B | 1.52B | 2.78B | 3.04B | 2.62B | 2.09B | 1.84B | 1.85B | 1.56B | 1.36B | 1.29B | 1.13B | 1.04B | 1.17B | 827.43M | 828.01M | 784.24M | 727.75M | 686.09M |
| EBIT | 7.28B | 8.81B | 7.62B | 7.36B | 8.62B | 8.62B | 5.68B | 4.89B | 3.6B | 3.11B | 1.72B | 3.36B | 2.68B | 2.09B | 714M | 6.22B | 6.51B | 7.4B | 6.38B | 5.06B | 2.69B | 4.86B | 4.33B | 3.07B | 3.26B | 3.22B | 3.4B | 3.15B | 3.12B | 2.83B | 2.62B |
| Net Interest Income | -706M | -111M | -259M | -313M | -132M | -367M | -662M | -724M | -624M | -756M | -205M | -73M | -87M | 20M | -350M | -932.95M | -695.68M | -72.88M | -327.25M | -456.39M | -292.35M | -153.66M | -149.09M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest Income | 237M | 230M | 344M | 385M | 183M | 43M | 46M | 94M | 105M | 124M | 99M | 105M | 77M | 67M | 59M | 85.2M | 105.45M | 137.78M | 201.23M | 136.75M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 943M | 341M | 603M | 698M | 315M | 410M | 708M | 818M | 729M | 880M | 304M | 178M | 164M | 47M | 409M | 1.02B | 801.13M | 210.66M | 528.47M | 593.14M | 416.17M | 241.35M | 200.21M | 146.12M | 205.22M | 234.76B | 23.22M | 0 | 0 | 0 | 0 |
| Other Income/Expense | -671M | 418M | 188M | 229M | -56M | -989M | -323M | -514M | -971M | 259M | -1.84B | 234M | -398M | -105M | -1.7B | -1.64B | -1.34B | 623.03M | -232.81M | -475.9M | -2.06B | -29.48M | -51.73M | 411.88M | 143.27M | -10.88M | 415.83M | 247.53M | 123.98M | 84.17M | 52.44M |
| Pretax Income | 6.56B | 8.47B | 7.01B | 6.66B | 8.31B | 8.21B | 4.97B | 4.08B | 2.87B | 2.23B | 1.41B | 3.18B | 2.52B | 2.52B | 6.26B | 5.2B | 5.71B | 7.19B | 5.86B | 4.47B | 2.28B | 4.62B | 4.13B | 3.73B | 3.67B | 1.88B | 3.82B | 3.4B | 3.24B | 2.95B | 2.67B |
| Pretax Margin % | 13.61% | 19.1% | 16.72% | 16.61% | 19.03% | 19.06% | 14.36% | 12.78% | 9.4% | 8.15% | 6.78% | 15.6% | 12.44% | 11.54% | 15.71% | 13.38% | 16.25% | 23.38% | 19.83% | 17.25% | 10.13% | 20.68% | 20.96% | 18.98% | 20.77% | 11.56% | 27.76% | 25.78% | 25.97% | 24.82% | 24.24% |
| Income Tax | 1.86B | 1.94B | -6.39B | 941M | 1.37B | 1.14B | 497M | 390M | 539M | 1.88B | 350M | 577M | 797M | 138M | 300M | 470M | 1.09B | 1.45B | 1.12B | 863.33M | 559.62M | 1.25B | 949.76M | 981.18M | 879.71M | 332.76M | 1.03B | 951.13M | 907.37M | 855.48M | 787.52M |
| Effective Tax Rate % | 28.36% | 22.94% | -91.1% | 14.12% | 16.53% | 13.88% | 10% | 9.57% | 18.76% | 84.18% | 24.77% | 18.13% | 31.65% | 5.47% | 4.79% | 9.04% | 19.03% | 20.13% | 19.16% | 19.32% | 24.58% | 27.01% | 23.02% | 26.27% | 23.95% | 17.67% | 27% | 28% | 28% | 29% | 29.5% |
| Net Income | 4.7B | 6.52B | 13.4B | 5.72B | 6.93B | 7.07B | 4.5B | 3.69B | 2.37B | 477M | 1.4B | 4.42B | 2.28B | 2.58B | 5.96B | 4.73B | 4.63B | 5.75B | 4.88B | 3.61B | 1.72B | 3.37B | 3.24B | 2.75B | 2.79B | 1.55B | 2.79B | 2.45B | 2.33B | 2.08B | 1.88B |
| Net Margin % | 9.75% | 14.72% | 31.95% | 14.27% | 15.88% | 16.42% | 12.99% | 11.56% | 7.74% | 1.74% | 6.71% | 21.68% | 11.28% | 11.79% | 14.95% | 12.17% | 13.15% | 18.68% | 16.53% | 13.92% | 7.64% | 15.1% | 16.44% | 13.99% | 15.8% | 9.52% | 20.27% | 18.56% | 18.71% | 17.5% | 17.09% |
| Net Income Growth % | -66.37% | -51.32% | 134.18% | -17.45% | -1.95% | 57.31% | 21.91% | 55.7% | 396.44% | -65.93% | -68.35% | 93.65% | -11.34% | -56.8% | 26.12% | 2.2% | -19.49% | 17.73% | 35.34% | 110.07% | -49.09% | 4.21% | 17.53% | -1.45% | 80.19% | -44.35% | 13.91% | 4.77% | 12.28% | 10.47% | 11.45% |
| Net Income (Continuing) | 4.7B | 6.52B | 13.4B | 5.72B | 6.93B | 7.07B | 4.47B | 3.69B | 2.33B | 353M | 1.06B | 2.61B | 1.72B | 1.99B | 237M | 1.13B | 4.63B | 5.75B | 4.73B | 3.61B | 1.72B | 3.37B | 3.18B | 2.5B | 2.55B | 1.55B | 2.79B | 2.45B | 2.33B | 2.08B | 1.88B |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 24M | 0 | 34M | 124M | 337M | 1.82B | 563M | 588M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 60.02M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 596M | 641M | 237M | 224M | 219M | 222M | 219M | 213M | 198M | 201M | 179M | 115M | 113M | 96M | 92.27M | 86.31M | 88.33M | 43.1M | 39.14M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | 2.71 | 3.72 | 7.64 | 3.27 | 3.91 | 3.94 | 2.50 | 2.06 | 1.34 | 0.27 | 0.94 | 2.94 | 1.50 | 1.64 | 3.75 | 3.01 | 2.97 | 3.70 | 3.13 | 2.31 | 1.12 | 2.16 | 2.06 | 1.75 | 1.78 | 0.99 | 1.78 | 1.57 | 1.49 | 1.33 | 1.19 |
| EPS Growth % | -66.16% | -51.31% | 133.64% | -16.37% | -0.76% | 57.6% | 21.36% | 53.73% | 396.3% | -71.28% | -68.03% | 96% | -8.54% | -56.27% | 24.58% | 1.35% | -19.73% | 18.21% | 35.5% | 106.25% | -48.15% | 4.85% | 17.71% | -1.69% | 79.8% | -44.38% | 13.38% | 5.37% | 12.03% | 11.76% | 12.26% |
| EPS (Basic) | - | 3.74 | 7.67 | 3.30 | 3.94 | 3.97 | 2.52 | 2.07 | 1.35 | 0.27 | 0.95 | 3.00 | 1.51 | 1.66 | 3.78 | 3.01 | 2.99 | 3.72 | 3.16 | 2.34 | 1.12 | 2.17 | 2.07 | 1.76 | 1.79 | 1.00 | 1.80 | 1.59 | 1.52 | 1.35 | 1.21 |
| Diluted Shares Outstanding | 1.74B | 1.75B | 1.75B | 1.75B | 1.76B | 1.79B | 1.79B | 1.78B | 1.77B | 1.75B | 1.48B | 1.51B | 1.53B | 1.57B | 1.59B | 1.57B | 1.56B | 1.55B | 1.56B | 1.56B | 1.54B | 1.56B | 1.57B | 1.57B | 1.57B | 1.57B | 1.57B | 1.56B | 1.56B | 1.58B | 1.58B |
| Basic Shares Outstanding | 1.73B | 1.75B | 1.73B | 1.73B | 1.75B | 1.77B | 1.77B | 1.77B | 1.76B | 1.74B | 1.47B | 1.47B | 1.51B | 1.55B | 1.58B | 1.57B | 1.55B | 1.55B | 1.54B | 1.54B | 1.53B | 1.55B | 1.56B | 1.56B | 1.56B | 1.55B | 1.55B | 1.54B | 1.54B | 1.55B | 1.56B |
| Dividend Payout Ratio | - | 63.09% | 28.62% | 62.14% | 47.73% | 45.28% | 56.95% | 61.57% | 83.36% | 387.63% | 109.93% | 32.62% | 58.76% | 34.24% | 53.38% | 62.14% | 57.75% | 42.02% | 44.55% | 54.33% | 103.52% | 50.01% | 49.44% | 44% | 51.11% | 81.97% | 41.13% | 41.02% | 38.2% | 38.94% | 38.69% |
Quick answers to the most common questions about buying ABT stock.
For fiscal year 2025, Abbott Laboratories (ABT) reported total revenue of $44.33B. This represents a 302.5% increase compared to $11.01B in 1996.
Abbott Laboratories (ABT) is profitable, generating $6.52B in net income for the fiscal year ending 2025 with a net profit margin of 14.7%.
Abbott Laboratories (ABT) reported an operating income of $8.05B, resulting in an operating profit margin of 18.2%. This margin reflects the operational efficiency of the business before interest and taxes.
Abbott Laboratories (ABT) generated $24.61B in gross profit for the year, representing a gross profit margin of 55.5%. This demonstrates the company's core pricing power and production efficiency.
Key Metrics
Top Statement Risk
Legal and regulatory exposure concentration
Metrics are mathematically derived from official filings.
Revenue Growth Steadying Near Mid-Single Digits
According to the reported quarterly income statements, ABT's revenue grew 14.5% year over year in the latest quarter after 4.0% growth two years earlier, a pattern that suggests growth has been volatile rather than structurally accelerating across the ten-quarter window reviewed here. Investors should weigh whether the recent step-up is durable.
The quarterly series shows revenue expanding from roughly $10.4 billion to $13.0 billion, but the year-over-year rates swing sharply, which may reflect pricing, volume, or the roll-off of pandemic-related diagnostics sales rather than a single consistent driver. The 5.7% trailing growth figure in the peer context appears more representative of underlying momentum than the single-quarter spikes. Warranting further investigation is how much of the latest acceleration is organic versus timing-driven.
Gross Margin Expanding Within a Narrow Band
Based on reported figures, ABT's gross margin moved from 51.0% to 56.8% over the period, a structural improvement that may reflect mix shift toward higher-margin Medical Devices, though the magnitude remains below the 65% to 78% gross margins posted by MDT, BSX, and EW.
The 5 to 6 percentage point expansion is meaningful for a diversified conglomerate and suggests the Medical Devices and diabetes care franchises are contributing disproportionately to profit. However, the gap to pure-play medtech peers implies the Nutritionals and Established Pharmaceuticals segments continue to dilute blended margins. Investors should monitor whether further expansion is achievable without pricing concessions.
Operating Margin Recovery Lags Gross Expansion
As reported in the income statements, ABT's operating margin compressed to 10.4% in the latest quarter from 19.6% in the prior year's fourth quarter, indicating that operating expenses have been absorbing a growing share of gross profit despite expanding gross margins.
Operating income has declined in absolute terms across recent quarters even as gross profit held near $6.3 to $7.4 billion, which points to negative operating leverage rather than scaling efficiency. SG&A and R&D together appear to be rising faster than gross profit, a pattern that warrants scrutiny of overhead discipline. The gap versus the 18.2% trailing operating margin suggests the most recent quarter may contain elevated one-time or seasonal costs that should be verified.
Reported Earnings Volatility Obscures Core Trend
Based on reported figures, ABT's diluted EPS ranged from $0.53 to $5.27 across the ten quarters, with the $5.27 quarter in late 2024 likely distorted by non-operating or one-time items, making the reported earnings trajectory difficult to interpret without adjustment.
Net income in the 2024Q4 period of roughly $9.2 billion is wildly disproportionate to operating income of $2.0 billion, a discrepancy that suggests substantial non-operating gains or accounting adjustments. Stock-based compensation remains modest relative to revenue, so it does not explain the anomaly. Analysts should normalize earnings before drawing conclusions about profitability trends.
Short-Thesis Risks Center on Litigation and Compression
The strongest bear argument, based on reported quarterly figures, is that operating margin has fallen from roughly 18% to 10% in the most recent quarter while legal exposure accounts for about 32% of tracked risk factors, potentially signaling margin pressure that management has not yet explained.
If the latest operating margin reflects a durable shift rather than a temporary cost event, the current valuation may embed expectations the income statement does not yet support. Litigation tied to pediatric nutrition and device claims could add unquantified charges that the reported figures do not fully capture. The absence of forward guidance in the latest report leaves investors without management's view on whether this compression is transitory.